Welcome to our dedicated page for Catalent news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent stock.
Catalent, Inc. (historically NYSE: CTLT) generates frequent news as a global contract development and manufacturing organization (CDMO) serving pharma, biotech, and consumer health customers. Company announcements emphasize its mission to develop, manufacture, and supply products that help people live better and healthier lives, as well as its role in optimizing product development, launch, and full life-cycle supply.
News about Catalent often covers its corporate transactions and ownership structure. A major recent theme has been the acquisition of Catalent by Novo Holdings A/S, a global life sciences investment firm. Press releases detail the signing of the merger agreement, regulatory approvals, fulfillment of closing conditions, and the completion of the all-cash transaction, after which Catalent became a private company and its common stock ceased trading on the New York Stock Exchange.
Operational updates are another key news category. Catalent has reported expansions of its global network, such as the completion of a significant expansion at its Schorndorf, Germany clinical supply facility, adding temperature-controlled storage, a new automatic bottle filling line, and dedicated space for its FastChain demand-led supply service. The company has also announced portfolio changes, including an agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, New Jersey, which also houses its corporate headquarters during a transition period.
Financial results and segment performance feature prominently in Catalent’s news flow. The company publishes quarterly and annual results, including net revenue, segment performance for Biologics and Pharma and Consumer Health, and non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Income, along with commentary on trends in non-COVID revenue and leverage ratios.
Governance and leadership developments also appear in Catalent’s news, such as new Board appointments and updates to its Board composition under Novo Holdings’ ownership. For readers tracking CTLT-related developments, this news stream provides context on Catalent’s evolution from a public CDMO to a privately held company, its investment in global capacity, and its ongoing role in supporting the development and supply of treatments worldwide.
Catalent, Inc. (NYSE: CTLT) will release its financial results for Q2 fiscal 2021 on February 2, 2021, before market open. A webcast discussing these results will be hosted at 8:15 a.m. ET the same day. The company, a leader in advanced delivery technologies and manufacturing solutions for healthcare products, generated over $3 billion in revenue in fiscal 2020. The webcast and supplemental materials will be accessible via Catalent's website.
Catalent, Inc. (NYSE: CTLT) announced that its executive leadership team will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 8:20 a.m. ET. A live webcast of the presentation can be accessed at investor.catalent.com, with a replay available post-event.
Catalent is a leading provider of advanced delivery technologies and solutions for drugs and biologics, generating over $3 billion in revenue in fiscal 2020 and employing over 14,000 people globally.
Catalent, Inc. (NYSE: CTLT) announced that its executive leadership team will present at two virtual investor conferences. The first is on November 16, 2020, at 10:00 a.m. ET for the Stephens Annual Investment Conference, followed by the Jefferies London Healthcare Conference on November 17, 2020, at 10:50 a.m. ET. Both presentations will be available via live webcast at investor.catalent.com with replays accessible post-event. Catalent is a global leader in advanced delivery technologies and generated over $3 billion in revenue in FY 2020.
Catalent, Inc. (CTLT) reported a strong first quarter for fiscal 2021 with net revenue reaching $845.7 million, a 27% increase compared to the prior year. Biologics revenue doubled year-over-year, contributing 44% to total revenue. Net earnings for common shareholders were $68.8 million or $0.42 per share, a recovery from a net loss in the same quarter last year. The company raised its annual guidance for net revenue to $3.58 billion to $3.78 billion, with adjusted EBITDA projected between $880 million and $950 million.
Catalent, Inc. (NYSE: CTLT) will release its financial results for Q1 fiscal year 2021, ended September 30, 2020, on November 3, 2020, before the market opens. A management webcast is scheduled for 8:15 a.m. ET the same day to discuss these results. Access to the webcast and a supplemental slide presentation will be available through the company's website. Catalent is recognized for its advanced delivery technologies and has generated over $3 billion in annual revenue, employing approximately 14,000 people across 45 facilities.